Senior Director - Oncology and Peripheral Imaging Clinical Development

About the role

The Senior Director, Imaging Clinical Research Physician leads the clinical development of oncology and peripheral imaging, spanning early and late-phase development. This role involves defining clinical strategies, endpoints, patient populations, and imaging criteria for each phase of development, serving as a scientific expert in oncology imaging modalities, analyzing and interpreting molecular imaging data, and providing strategic input into the development of advanced image analysis methods.

Responsibilities

• Lead the design and execution of integrated clinical development programs for oncology and peripheral imaging across early and late-phase development.
• Define clinical strategies, endpoints, patient populations, and imaging criteria for each phase of development.
• Design studies to evaluate diagnostic accuracy, optimal imaging timing, patient selection biomarkers, and comparative performance versus standard-of-care imaging.
• Serve as a scientific expert in oncology imaging modalities, including PET, SPECT, CT, MRI, and emerging theranostic platforms.
• Analyze and interpret molecular imaging data (e.g., PET/CT, SPECT/CT), including tumor localization, tracer biodistribution, dosimetry considerations, and longitudinal response assessment.
• Evaluate and interpret imaging biomarkers for patient stratification, response assessment, and disease monitoring across solid tumors and hematologic malignancies.
• Evaluate imaging performance metrics such as sensitivity, specificity, standardized uptake values (SUVs), and tumor to background ratios.
• Apply knowledge of immune-mediated, cardiovascular, and metabolic disease biology to support imaging programs beyond oncology, as applicable.
• Collaborate internally with imaging physicians, medical oncologists, medical physicists, as well as with imaging operations and advanced analysis teams.
• Lead cross-functional projects and coordinate with external partners, including CROs, academic institutions, software developers, and scanner manufacturers, to support imaging method validation and implementation.
• Evaluate emerging scientific and technological advances in imaging, including modeling approaches and artificial intelligence, and drive their application in clinical programs.
• Author and review key clinical and regulatory documents, including Investigator’s Brochures, protocols, protocol amendments, clinical study reports, and regulatory briefing documents.
• Contribute to the development of technical manuals and imaging-related trial documentation.
• Communicate scientific findings through internal presentations, conference abstracts, and peer-reviewed publications.

Requirements

• Medical Doctor must be board eligible or certified in a medical specialty relevant to the role or have completed the comparable level of post-medical school clinical training relevant to the country of hiring.
• U.S. trained physicians must have achieved board eligibility or certification.
• Foreign medical graduates in U.S. based jobs, who are not U.S. board eligible or certified may be hired directly for employment in the U.S. at the discretion of the Chief Medical Officer.
• For the recognized list of foreign medical schools and the disapproved list, see here.
• Minimum 3 years clinical development experience in industry.

Basic Requirements

• Minimum 3 years clinical development experience in industry.
• Industry experience.

Additional Skills/Preferences

• Tracer development experience and experience in oncology and peripheral (non CNS) imaging is highly preferred.
• Strong problem-solving skills; able to anticipate and recognize systemic problems, diagnose root causes and take corrective actions to prevent reoccurrence.
• Familiarity with Good Clinical Practice (GCP) and regulatory requirements.
• Strong ability to balance scientific and business priorities.
• Demonstrated communication, collaboration, organizational, and influencing skills.
• Fluency in written and spoken English.
• Travel estimated at 10-15%.